Along with the revisions to the Japanese quasi-drug ingredient standards on March 25, 2021, Japan Ministry of Health, Labour and Welfare (MHLW) also revised the relevant application requirements for the manufacture and sale of quasi-drugs.
The revised requirements came into effect on the date of promulgation.